In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
In the latest session, Ovid Therapeutics Inc (NASDAQ: OVID) closed at $0.55 up 14.75% from its previous closing price of $0.48. In other words, the price has increased by $14.75 from its previous closing price. On the day, 3.4 million shares were traded. OVID stock price reached its highest trading level at $0.57 during the session, while it also had its lowest trading level at $0.48.
Ratios:
For a deeper understanding of Ovid Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.93 and its Current Ratio is at 4.93. In the meantime, Its Debt-to-Equity ratio is 0.24 whereas as Long-Term Debt/Eq ratio is at 0.22.
On April 30, 2024, B. Riley Securities started tracking the stock assigning a Buy rating and target price of $9.
On April 29, 2024, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $9.H.C. Wainwright initiated its Buy rating on April 29, 2024, with a $9 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Feb 26 ’25 when ALEXANDER MARGARET A. sold 5,279 shares for $0.56 per share. The transaction valued at 2,956 led to the insider holds 73,406 shares of the business.
Rona Jeffrey A sold 3,902 shares of OVID for $2,185 on Feb 26 ’25. The CBFO now owns 67,973 shares after completing the transaction at $0.56 per share. On Jan 27 ’25, another insider, ALEXANDER MARGARET A., who serves as the President and COO of the company, bought 6,810 shares for $0.73 each. As a result, the insider paid 4,971 and bolstered with 34,935 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, OVID now has a Market Capitalization of 39110228 and an Enterprise Value of -5106971. For the stock, the TTM Price-to-Sale (P/S) ratio is 71.11 while its Price-to-Book (P/B) ratio in mrq is 0.66. Its current Enterprise Value per Revenue stands at -9.319 whereas that against EBITDA is 0.097.
Stock Price History:
The Beta on a monthly basis for OVID is 0.18, which has changed by -0.4660194 over the last 52 weeks, in comparison to a change of 0.13161862 over the same period for the S&P500. Over the past 52 weeks, OVID has reached a high of $1.47, while it has fallen to a 52-week low of $0.24. The 50-Day Moving Average of the stock is 68.07%, while the 200-Day Moving Average is calculated to be -17.67%.
Shares Statistics:
For the past three months, OVID has traded an average of 1.34M shares per day and 3594600 over the past ten days. A total of 71.11M shares are outstanding, with a floating share count of 59.51M. Insiders hold about 16.32% of the company’s shares, while institutions hold 47.83% stake in the company. Shares short for OVID as of 1749772800 were 2498318 with a Short Ratio of 0.93, compared to 1747267200 on 1628743. Therefore, it implies a Short% of Shares Outstanding of 2498318 and a Short% of Float of 4.2.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
